David S. Ettinger, Debra K. Armstrong, Sally Barbour, Michael J. Berger, Philip J. Bierman, Bob Bradbury, Georgianna Ellis, Steve Kirkegaard, Dwight D. Kloth, Mark G. Kris, Dean Lim, Michael Anne Markiewicz, Lida Nabati, Carli Nesheiwat, Hope S. Rugo, Steven M. Sorscher, Lisa Stucky-Marshal, Barbara Todaro, Susan Urba

Research output: Contribution to journalReview articlepeer-review

29 Scopus citations


Chemotherapy-induced nausea and vomiting (emesis) can significantly affect a patient's quality of life, leading to poor adherence with further chemotherapy treatment. In addition, nausea and vomiting can result in other serious complications and deterioration of the patient's status. These guidelines explore the prevention, treatment, and management of various types of emesis experienced by cancer patients, such as breakthrough, radiation-induced, and anticipatory. The latest 2009 NCCN Guidelines include updated dosing recommendations for palonosetron and dexamethasone and the inclusion of the granisetron transdermal patch after FDA approval.

Original languageEnglish (US)
Pages (from-to)572-595
Number of pages24
JournalJNCCN Journal of the National Comprehensive Cancer Network
Issue number5
StatePublished - May 2009


  • 5-HT3-receptor antagonists
  • Antiemesis
  • Chemotherapy-induced
  • NCCN Clinical Practice Guidelines
  • NK-1-receptor antagonists
  • Nausea and vomiting

ASJC Scopus subject areas

  • Oncology


Dive into the research topics of 'Antiemesis'. Together they form a unique fingerprint.

Cite this